Clinical data | |
---|---|
Trade names | Daxas, Daliresp, Zoryve, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611034 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, topical |
Drug class | PDE4 inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 79%[4][3][8][9] |
Protein binding | 99%[4][3][8][9] |
Metabolism | Hepatic via CYP1A2 & CYP3A4[4][3][8][9] |
Elimination half-life | 17 hours (30 hours [active metabolite])[4][3][8][9] |
Excretion | Urine (70%)[4][3][8][9] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.210.960 |
Chemical and physical data | |
Formula | C17H14Cl2F2N2O3 |
Molar mass | 403.21 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Roflumilast, sold under the brand name Daxas among others, is a medication used for the treatment of chronic obstructive pulmonary disease,[4] plaque psoriasis,[5] seborrheic dermatitis,[6] and atopic dermatitis.[5] It acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4).[10] It has anti-inflammatory effects.[10][11][12]
It was approved for medical use in the European Union in 2010,[7] in the United States in 2011,[4] and in Canada in 2017.[1] It is available as a generic medication.[13]
Daxas SmPC
was invoked but never defined (see the help page).Zoryve cream FDA label
was invoked but never defined (see the help page).Zoryve foam FDA label
was invoked but never defined (see the help page).EMA
was invoked but never defined (see the help page).MSR
was invoked but never defined (see the help page).